LATAM MedTech Insights

In this episode of LATAM MedTech Insights, we break down the critical new IVD regulation in Brazil, RDC 830/2023. This isn't just another update; it's a complete overhaul that aligns In-Vitro Diagnostic devices with the stringent framework of the general medical device regulation, RDC 751/2022, creating a new set of rules and unexpected hurdles for manufacturers. We uncover the hidden complexities...

Brazil just added a complex new layer to its AI MedTech regulations. Last week, the Federal Council of Medicine (CFM) issued Resolution 2,454, a framework that directly impacts how physicians can use AI tools. This isn't about device registration through ANVISA; it's about winning the trust and acceptance of the end-users—the doctors themselves. This episode dives deep into what this resolution me...

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for foreign manufacturers. We explore the specific documentation now required and what this means for anyone trying to enter Latin America's largest market. This move signals a maj...

This week, we dissect a game-changing announcement from Brazil's ANVISA: a new "fast-track" approval process for AI-powered medical devices. While it promises rapid market access, it hides significant challenges beneath the surface that could derail unprepared international companies. This episode explores how Brazil's stringent data privacy law, the LGPD, is interwoven into this new regulatory pa...

Last week, Brazil's regulatory agency, ANVISA, issued an unexpected technical guidance that reclassifies certain Software as a Medical Device (SaMD) products. This move has sent shockwaves through the digital health sector, pushing many devices that rely on predictive algorithms into higher-risk categories overnight, invalidating existing registrations. In this episode of LATAM MedTech Insights, w...

This week on LATAM MedTech Insights, we dive into the significant new regulatory guidance from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). This update brings Brazil closer to global standards but introduces critical new challenges for foreign manufacturers in areas like risk classification, AI validation, and cybersecurity. We explore the immediate impa...

This week, we dive into a major regulatory shift in Brazil that just went live on March 1st, 2026. ANVISA's new Normative Instruction N°426/2026 activates the national UDI (Unique Device Identification) database, requiring manufacturers to submit detailed product data before entering the market. This episode breaks down the new requirements, the critical phased deadlines for different device class...

This episode of LATAM MedTech Insights, brought to you by Pure Global, dives into the landmark regulatory shift just implemented by Brazil's ANVISA. We unpack the new RDC 830/2023 resolution for In-Vitro Diagnostic (IVD) devices, a critical update that redefines market access and compliance in Latin America's largest market. We explore how this harmonization with global standards impacts everythin...

A seismic regulatory shift is underway in Brazil, Latin America's biggest MedTech market. ANVISA's new Unique Device Identification (UDI) system, detailed in Normative Instruction 426/2026, is now being implemented. This isn't just a new labeling rule; it's a complex data management and submission challenge that could become a major barrier to market entry for unprepared device manufacturers. This...

Brazil's MedTech market just experienced a seismic shift. ANVISA, the national regulatory agency, has rolled out its new comprehensive framework, RDC 751, fundamentally changing the rules for medical device registration and market access. This move aligns Brazil closer than ever with international standards like the EU MDR. In this episode, we break down what this massive overhaul means for manufa...

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA, RDC 989, which establishes a new fast-track approval pathway for AI-driven diagnostic software. This is a pivotal moment for the MedTech industry in Latin America, promising to accelerate innovation and market access. However, this opportunity comes with significant new hurdles. The regulation introduces complex requirem...

Brazil's national regulatory agency, ANVISA, has unexpectedly accelerated the compliance deadlines for its Unique Device Identification (UDI) system, creating a significant new challenge for MedTech manufacturers. This sudden shift requires immediate action on labeling, data management, and submission strategies to avoid market disruption. While this presents a major hurdle, it also offers a compe...

This week, we dissect a sudden and significant regulatory enforcement shift from Brazil's ANVISA. The agency has accelerated the implementation of its comprehensive UDI traceability system for high-risk medical devices, a key part of its 2026-2027 agenda to harmonize with global standards. This move is catching many international manufacturers off guard, creating immediate challenges for market ac...

Brazil's regulatory agency, ANVISA, is launching a major digital overhaul for 2026, promising to slash approval times and streamline market access for medical devices. This episode dives into the core of ANVISA's new agenda, from the 'AnvisAI' project aimed at modernizing submissions to new fast-track queues for lower-risk devices. We explore how this digital transformation is creating unprecedent...

This week on LATAM MedTech Insights, we dissect the groundbreaking news from Brazil's ANVISA. A new fast-track approval pathway for AI-powered medical software has just been announced, promising to revolutionize market access in Latin America's largest market. This is the opportunity the industry has been waiting for, but it comes with a complex twist. This newfound speed is coupled with a formida...

In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt. This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore th...

This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard. We explore why existing FDA or CE Mark documentation is no long...

This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico. We dive i...

Brazil's health agency, ANVISA, has just introduced a stringent new cybersecurity regulation for all connected medical devices. This sudden move, aimed at enhancing patient safety and data protection, presents immediate and complex challenges for manufacturers. It escalates compliance costs and extends timelines, demanding a new level of technical documentation that many were not prepared for. Thi...

This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology. But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-mark...

This week, we dive into a critical regulatory update from Brazil. ANVISA has just rolled out a new resolution that reshapes the essential safety and performance requirements for medical devices, placing a heavy new emphasis on lifecycle risk management and international harmonization. This change impacts everything from technical file preparation to post-market surveillance. We explore the specifi...

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just launched a new, expedited approval pathway for AI-powered medical software, potentially slashing market entry timelines. This episode breaks down the immense opportunity this presents for MedTech innovators looking to enter Latin America's largest market. But there's a critical catch. This accelerated access comes with...

This week on LATAM MedTech Insights, we analyze the seismic new draft regulation from Brazil's ANVISA that is set to overhaul the rules for Software as a Medical Device (SaMD). This proposal introduces stringent new requirements for AI technologies and local data management, promising to reshape market access for all foreign MedTech companies targeting Brazil. We dive into the real-world impact by...

Brazil's regulatory agency, ANVISA, has just rolled out game-changing new rules that create a fast-track pathway for high-risk medical devices. This episode breaks down the new "reliance" mechanism that allows manufacturers to use existing international approvals for quicker market access, and what the new clinical trial law means for MedTech innovation. We explore how these changes are dismantlin...

In this episode, we dissect the groundbreaking news from Brazil's health agency, ANVISA. Last week, they launched "Agiliza IA Saúde," a new fast-track approval program for AI-powered medical software. This move could unlock massive opportunities in Latin America's largest market, promising to slash registration times for innovative diagnostic technologies. While the opportunity is immense, it come...